Blocking CD38 Protects Brain Blood Vessels and Reverses Dementia in Mice
A selective CD38 inhibitor restores blood-brain barrier integrity and improves cognition in a mouse model of vascular dementia.
Summary
Vascular dementia (VaD) damages the brain's blood vessels and impairs cognition through inflammation and blood-brain barrier breakdown. Researchers found that the enzyme CD38 is elevated in brain endothelial cells during VaD and drives much of this damage. Using a mouse model of chronic cerebral hypoperfusion, they showed that blocking CD38 with the inhibitor compound 78c reduced inflammation, restored tight junction proteins that seal the blood-brain barrier, improved cerebral blood flow, and lessened white matter injury. Lab experiments pointed to the NOX4/eNOS signaling axis as the likely mechanism. These findings position CD38 as a promising drug target for protecting the brain's vascular system in dementia.
Detailed Summary
Vascular dementia is the second most common form of dementia worldwide, yet targeted therapies remain limited. It is driven by impaired blood flow to the brain, leading to endothelial cell dysfunction, blood-brain barrier (BBB) breakdown, and chronic neuroinflammation — a cascade that progressively destroys white matter and cognitive function. Identifying molecular drivers of this cascade is essential for developing effective treatments.
Researchers from Tianjin Medical University focused on CD38, an enzyme known to promote neuroinflammation and cellular senescence. While CD38 has been studied in aging and other neurological conditions, its specific role in cerebrovascular endothelial cell (CEC) dysfunction in VaD had not been established. The team used the bilateral common carotid artery stenosis (BCAS) mouse model, a well-validated method for inducing chronic cerebral hypoperfusion and VaD-like pathology.
BCAS mice showed significantly reduced cerebral blood flow, increased BBB permeability, cognitive deficits, and elevated expression of CD38 in CECs alongside surges in pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Treatment with the selective CD38 inhibitor 78c (10 mg/kg, twice daily for one month) reversed many of these effects — restoring CBF, upregulating tight junction proteins critical for BBB integrity, reducing white matter damage, and suppressing neuroinflammation.
In vitro experiments using TNF-α-stimulated CECs confirmed that 78c reduces CD38 expression and inflammatory signaling, likely by modulating the NOX4/eNOS axis — a pathway linking oxidative stress to nitric oxide regulation in vascular endothelium.
These findings are compelling but carry important caveats. The study relies on a single animal model and a single inhibitor compound, and the precise mechanistic pathway requires further validation. Human translation remains distant. Nonetheless, CD38 emerges as a credible, druggable target for neurovascular protection in vascular dementia.
Key Findings
- CD38 expression is significantly elevated in brain endothelial cells in a mouse VaD model.
- CD38 inhibitor 78c improved cerebral blood flow and restored blood-brain barrier tight junction proteins.
- 78c reduced pro-inflammatory cytokines IL-1β, IL-6, and TNF-α and alleviated white matter damage.
- In vitro, 78c suppressed TNF-α-induced CD38 and inflammation via the NOX4/eNOS signaling axis.
- Cognitive deficits in BCAS mice were measurably improved following one month of 78c treatment.
Methodology
Researchers used the bilateral common carotid artery stenosis (BCAS) mouse model to induce chronic cerebral hypoperfusion and VaD-like pathology. CD38 inhibitor 78c was administered at 10 mg/kg twice daily for one month, with cognitive, vascular, and inflammatory endpoints assessed. Complementary in vitro experiments used TNF-α-stimulated cerebrovascular endothelial cells to probe mechanistic pathways.
Study Limitations
The study uses only one animal model (BCAS) and one inhibitor compound, limiting generalizability. The proposed NOX4/eNOS mechanism is suggestive but not fully validated through genetic or pathway-specific knockdown experiments. Human clinical relevance has not yet been demonstrated, and long-term safety of CD38 inhibition in the brain remains unknown.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.